Antitumor activity of a novel series of α-aryloxy-α- methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines

Investigational New Drugs

Volumn 27, Issue 3, 2009, Pages 223-232

  Xiong, Xishan ^a   Ye, Yangliang ^b   Fu, Lili ^a   Dai, Bing ^a   Liu, Jieqiong ^a   Jia, Jieshuang ^a   Tang, Jing ^b   Li, Lin ^a   Wang, Li ^a   Shen, Jianhua ^b   Mei, Changlin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

aryloxy methylhydrocinnamic acid derivative; A549; Apoptosis; Cell cycle; IC50; Peroxisome proliferator activated receptor gamma

Indexed keywords

ALPHA ARYLOXY ALPHA METHYLHYDROCINNAMIC ACID DERIVATIVE; CINNAMIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; L-LACTATE DEHYDROGENASE; PHENYLPROPIONATES; PPAR GAMMA; PROPIDIUM; THIAZOLIDINEDIONES;

EID: 64649097439     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9161-0     Document Type: Article

References (30)

1. J Berger DE Moller 2002 The mechanisms of action of PPARs Annu Rev Med 53 409 435
2. TM Willson MH Lambert SA Kliewer 2001 Peroxisome proliferator-activated receptor gamma and metabolic disease Annu Rev Biochem 70 341 367
3. FS Chou PS Wang S Kulp JJ Pinzone 2007 Effects of thiazolidinediones on differentiation, proliferation, and apoptosis Mol Cancer Res 5 523 530
4. MS Lin WC Chen X Bai YD Wang 2007 Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer J Dig Dis 8 82 88
5. YT Guo XS Leng T Li JM Zhao XH Lin 2004 Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats World J Gastroenterol 10 3419 3423
6. I Borbath I Leclercq P Moulin C Sempoux Y Horsmans 2007 The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver Eur J Cancer 43 1755 1763
7. T Kubota K Koshizuka EA Williamson H Asou JW Said S Holden 1998 Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Res 58 3344 3352
8. E Kebebew M Peng E Reiff P Treseler KA Woeber OH Clark 2006 A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer Surgery 140 960 966
9. E Mueller M Smith P Sarraf T Kroll A Aiyer DS Kaufman 2000 Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer Proc Natl Acad Sci USA 97 10990 10995
10. C Grommes GE Landreth MT Heneka 2004 Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists Lancet Oncol 5 419 429
11. C Freudlsperger A Thies U Pfuller U Schumacher 2007 The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells Anticancer Res 27 207 213
12. T Vogt C Hafner K Bross F Bataille KW Jauch A Berand 2003 Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors Cancer 98 2251 2256
13. GA Diamond S Kaul 2007 Rosiglitazone and cardiovascular risk N Engl J Med 357 938 939
14. DM Nathan 2007 Rosiglitazone and cardiotoxicity-weighing the evidence N Engl J Med 357 64 66
15. BM Psaty CD Furberg 2007 The record on rosiglitazone and the risk of myocardial infarction N Engl J Med 357 67 69
16. PV Devasthale S Chen Y Jeon F Qu C Shao W Wang 2005 Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl) ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities J Med Chem 48 2248 2250
17. JH Ahn MS Shin SH Jung SK Kang KR Kim SD Rhee 2006 Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists J Med Chem 49 4781 4784
18. KR Kim JH Lee SJ Kim SD Rhee WH Jung SD Yang 2006 KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects Biochem Pharmacol 72 446 454
19. DM Ray F Akbiyik RP Phipps 2006 The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms J Immunol 177 5068 5076
20. S Papineni S Chintharlapalli S Safe 2008 Methyl 2-Cyano-3,11-dioxo- 18beta-olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-gamma agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells Mol Pharmacol 73 553 565
21. S Chintharlapalli S Papineni S Safe 2007 1,1-bis(3'-indolyl)-1-(p- substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways Mol Pharmacol 71 558 569
22. DM Ray KM Morse SP Hilchey TM Garcia RE Felgar SB Maggirwar 2006 The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway Exp Hematol 34 1202 1211
23. S Han Y Zheng J Roman 2007 Rosiglitazone, an agonist of PPARgamma, inhibits non-small cell carcinoma cell proliferation in part through activation of tumor sclerosis complex-2 PPAR Res 2007 29632
24. VG Keshamouni DA Arenberg RC Reddy MJ Newstead S Anthwal TJ Standiford 2005 PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer Neoplasia 7 294 301
25. Xiong X, Fu L, Wang L, Cai H, Li L, Jiang H et al (2008) Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. Invest New Drugs, online first
26. KY Kim JH Ahn HG Cheon 2007 Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation Mol Pharmacol 72 674 685
27. S Han J Roman 2007 Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs 18 237 244
28. K Schoonjans B Staels J Auwerx 1996 The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation Biochim Biophys Acta 1302 93 109
29. SE Nissen K Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457 2471
30. S Theocharis A Margeli P Vielh G Kouraklis 2004 Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators Cancer Treat Rev 30 545 554